Company Encyclopedia
View More
name
SFPM
002737.SZ
Sunflower Pharmaceutical Group Co.,Ltd engages in the research and development, manufacturing, and marketing of Chinese patent medicines in China and internationally. The company produces chemical and biological medicines, and health care products. It also provides products covering various therapeutic areas, including pediatrics, gynecology, adult digestive system, respiratory and cold, rheumatic bone disease, and cardiovascular and cerebrovascular; supplements; tonic; and antibiotics and children’s medicinal products. The company sells its products under the Sunflower and Little Sunflower brands.
3.097 T
002737.SZMarket value -Rank by Market Cap -/-

Financial Score

20/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking189/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-3.01%D
    • Profit Margin-6.13%D
    • Gross Margin34.49%C
  • Growth ScoreE
    • Revenue YoY-52.75%E
    • Net Profit YoY-115.01%E
    • Total Assets YoY-13.63%E
    • Net Assets YoY-9.93%D
  • Cash ScoreE
    • Cash Flow Margin-1631.85%E
    • OCF YoY-52.75%E
  • Operating ScoreC
    • Turnover0.38C
  • Debt ScoreA
    • Gearing Ratio17.40%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SFPM: The application for the registration and listing license of Fusidic Acid Cream has been accepted

    SFPM's wholly-owned subsidiary Harbin SFPM recently received the "Acceptance Notice" from the National Medical Products Administration regarding the application for the registration and marketing authorization of fusidic acid cream. This medication is primarily used to treat skin infections caused by various bacteria, with indications including pustules, boils, and carbuncles, suitable for facial and scalp infections

    Zhitong·
    SZ
    002737
    +0.53%
    Zhitong·
    SZ
    002737
    +0.53%

    SFPM and related personnel received a warning letter from the Heilongjiang Securities Regulatory Bureau

    SFPM recently received a warning letter from the Heilongjiang Securities Regulatory Bureau for failing to comply with the prescribed procedures for related party transaction review and information disclosure obligations. The transaction amount between the company and its wholly-owned subsidiary Shanghai Haiwei was 32.3836 million yuan, accounting for 0.68% of the most recent audited net assets. Chairman Guan Yuxiu, General Manager Guan Yi, and Board Secretary Zhou Guangkuao bear primary responsibility for this violation. The Heilongjiang Securities Regulatory Bureau has decided to take warning letter measures against them and record it in their integrity files

    Zhitong·
    SZ
    002737
    +0.53%
    Zhitong·
    SZ
    002737
    +0.53%

    SFPM: The application for the registration and listing license of Clobetasol Propionate Ointment has been accepted

    SFPM announced that its wholly-owned subsidiary Harbin SFPM received the "Acceptance Notice" from the National Medical Products Administration regarding the application for the registration and marketing authorization of Clobetasol Propionate Ointment. Clobetasol Propionate Ointment is suitable for topical treatment of mild to moderate atopic dermatitis in patients aged 3 months and older. The company will actively promote the marketing authorization process for this product and continuously monitor the approval status, fulfilling its information disclosure obligations in a timely manner

    Zhitong·
    SZ
    002737
    +0.53%
    Zhitong·
    SZ
    002737
    +0.53%

    SFPM: Net profit loss of 115 million yuan in the third quarter, a decrease of 214.27%

    SFPM announced that its revenue for the third quarter was 374 million yuan, a year-on-year decrease of 14.90%; the net profit loss was 115 million yuan, a decrease of 214.27%. The revenue for the first three quarters was 1.684 billion yuan, a year-on-year decrease of 43.24%; the net profit loss was 33.5387 million yuan, a decrease of 105.72%

    Zhitong·
    SZ
    002737
    +0.53%
    Zhitong·
    SZ
    002737
    +0.53%

    SFPM: Pediatric Lung Heat Cough and Wheezing Oral Solution approved to conduct clinical trials

    According to the Zhitong Finance APP, SFPM announced that its wholly-owned subsidiary Heilongjiang SFPM Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the clinical trial of the pediatric lung heat cough and asthma oral solution for use in children with acute bronchitis

    Zhitong·
    SZ
    002737
    +0.53%
    Zhitong·
    SZ
    002737
    +0.53%
    © 2025 Longbridge｜Disclaimer